✦ LIBER ✦

Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer

✍ Scribed by Bülent Karagöz; Oğuz Bilgi; Ahmet Alacacıoğlu; Alpaslan Özgün; Özkan Sayan; Alev Akyol Erikçi; Emin Gökhan Kandemir

Book ID: 107576822
Publisher: Springer US
Year: 2009
Tongue: English
Weight: 186 KB
Volume: 27
Category: Article
ISSN: 1357-0560
DOI: 10.1007/s12032-009-9191-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radiotherapy but not tamoxifen reduced t

Radiotherapy but not tamoxifen reduced the risk of invasive breast cancer after excision of ductal carcinoma in situ

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Adjuvant extension of chemotherapy after

Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancer

✍ M. Knauer; A. Haid; Y. Schneider; R. Köberle-Wührer; A. Lang; T. Winder; R. Alto 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 254 KB

Cost-effectiveness of exemestane versus

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden

✍ J. Lundkvist; Wilking; S. Holmberg; M. Lidgren; L. Jönsson 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 123 KB

86 Oncoplastic surgery but not objective

86 Oncoplastic surgery but not objectively measured symmetry after breast conserving therapy improves quality of life in breast cancer patients

✍ R. Exner; W. Krois; O. Riedl; H. Trischer; M. Mittlboeck; T. Wild; R. Jakez; M. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB

GYNECOMASTIA AND BREAST PAIN INDUCED BY

GYNECOMASTIA AND BREAST PAIN INDUCED BY ADJUVANT THERAPY WITH BICALUTAMIDE AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PROSTATE CANCER: THE ROLE OF TAMOXIFEN AND RADIOTHERAPY

✍ DI LORENZO, GIUSEPPE; PERDONÀ, SISTO; DE PLACIDO, SABINO; D’ARMIENTO, MASSIMO; G 📂 Article 📅 2005 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 705 KB

Switching to exemestane after 2–3 years

Switching to exemestane after 2–3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen: Abstracted from: Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.

✍ Christina Davies 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 248 KB